Somnomed Limited Stock Today
| SOMNF Stock | USD 0.17 0.01 5.56% |
Performance2 of 100
| Odds Of DistressLess than 24
|
SomnoMed is trading at 0.17 as of the 28th of November 2024. This is a 5.56 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.17. SomnoMed has about a 24 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for SomnoMed Limited are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2022 and ending today, the 28th of November 2024. Click here to learn more.
SomnoMed Limited, together with its subsidiaries, engages in the production and sale of devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific region. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia. The company has 78.56 M outstanding shares. More on SomnoMed Limited
Moving against SomnoMed Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
SomnoMed Pink Sheet Highlights
| Business Concentration | Medical Devices, Healthcare (View all Sectors) |
SomnoMed Limited [SOMNF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Micro-Cap' category with a current market capitalization of 71.36 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate SomnoMed's market, we take the total number of its shares issued and multiply it by SomnoMed's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. SomnoMed Limited classifies itself under Healthcare sector and is part of Medical Devices industry. The entity has 78.56 M outstanding shares.
SomnoMed Limited has accumulated about 15.64 M in cash with 1.86 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check SomnoMed Probability Of Bankruptcy
Ownership AllocationSomnoMed Limited shows a total of 78.56 Million outstanding shares. Over half of SomnoMed's outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check SomnoMed Ownership Details
SomnoMed Limited Risk Profiles
| Mean Deviation | 2.39 | |||
| Standard Deviation | 10.44 | |||
| Variance | 109.06 | |||
| Risk Adjusted Performance | 0.0288 |
SomnoMed Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in SomnoMed without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Companies Directory Now
Companies DirectoryEvaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
| All Next | Launch Module |
SomnoMed Corporate Management
| Christopher Bedford | VP of Global Production and Product Devel. | Profile | |
| Herv Fivet | Global Officer | Profile | |
| Marco Kleef | VP Europe | Profile | |
| BCom BComm | Company Sec | Profile | |
| Mark Harding | VP Marketing | Profile | |
| Jagdeep Bijwadia | Chief Officer | Profile | |
| MAICD MBA | Gen Operations | Profile |
Other Information on Investing in SomnoMed Pink Sheet
SomnoMed financial ratios help investors to determine whether SomnoMed Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in SomnoMed with respect to the benefits of owning SomnoMed security.